PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 28 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Cyclotides varv A, varv F, and cycloviolacin 02 exhibited strong dose-dependent cytotoxic activities across 10 human tumor cell lines, with cycloviolacin 02 being the most potent (IC50 0.1-0.3 microM) [PMID:12477048].
The synthetic VarvA cyclotide showed antimicrobial activity against various Gram-negative bacteria [PMID:29671790].
Evidence summary
PubMed sources
- 1.PMID: 12477048 (2002) — Cyclotides: a novel type of cytotoxic agents. · Molecular cancer therapeutics
- 2.PMID: 35929747 (2022) — Rapid evolution of selfing syndrome traits in Viola arvensis revealed by resurrection ecology. · American journal of botany
- 3.PMID: 29671790 (2018) — Chemical Synthesis and Functional Analysis of VarvA Cyclotide. · Molecules (Basel, Switzerland)
- 4.PMID: 35161360 (2022) — Classical Morphometrics in V. arvensis and V. kitaibeliana (Viola sect. Melanium) Reveals Intraspecific Variation with Implications for Species Delimitation: Inferences from a Case Study in Central Italy. · Plants (Basel, Switzerland)
- 5.PMID: 10075760 (1999) — Seven novel macrocyclic polypeptides from Viola arvensis.